Lantheus Holdings' analyst price target was reduced slightly to $83.21 from $84.29, as analysts factor in ongoing Pylarify pricing pressures and moderated revenue growth expectations, while continued profitability helps balance these concerns.

Analyst Commentary

Analyst sentiment regarding Lantheus Holdings has shifted recently, with both optimistic and cautious perspectives shaping the company's investment narrative. Recent research notes have highlighted several key factors contributing to the current outlook surrounding Lantheus' valuation, execution, and growth prospects.

• Bullish analysts maintain a Buy recommendation, even though recent price targets have been reduced. This reflects confidence in the company’s long-term growth and profitability potential.
• There is ongoing belief in the underappreciated value of Lantheus’ pipeline and royalty opportunities, such as Flyrcado and Pylclari.
• Domestic volumes for Pylarify remain positive, with year-over-year growth as market dynamics shift.
• Some analysts anticipate stabilization and recovery for Pylarify following the approval and rollout of newer, second-generation formulations in the coming years.

• Bearish analysts note uncertainty around Pylarify’s market share, with continued pricing pressure and competition affecting growth visibility and sales expectations.
• Recent downgrades and lowered price targets indicate a risk of further deceleration in revenues over the next two quarters, particularly as Pylarify trends remain volatile.
• Concerns have been raised about slower-than-expected adoption of key therapeutics and bolt-on acquisitions, which may obscure the trajectory of organic growth.
• The consensus is that share price recovery will likely depend on gaining greater clarity around the stabilization of Pylarify and a return to more predictable earnings performance.

What's in the News

• Lantheus Holdings and GE HealthCare entered an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize PYLARIFY in Japan for prostate cancer diagnostics. The deal includes upfront fees, potential development milestones, tiered royalties, and the formation of a joint steering committee.
• A class action lawsuit has been filed against Lantheus Holdings and certain executives, alleging misleading statements about Pylarify's growth potential and competition risks. Recent announcements of lowered sales projections led to significant drops in Lantheus stock price.
• The FDA accepted a New Drug Application for a new formulation of Lantheus' PSMA imaging agent, with a goal action date of March 6, 2026. The new formulation aims to improve manufacturing efficiency and expand patient access.
• Lantheus completed the repurchase of 2,375,873 shares for $199.94 million as part of its ongoing buyback program. The company has authorization for up to $400 million in share repurchases through 2027.
• Lantheus lowered its 2025 revenue guidance to $1.475 to $1.51 billion from a prior $1.55 to $1.585 billion range.

Valuation Changes

• Consensus Analyst Price Target has fallen slightly to $83.21 from $84.29, reflecting more cautious revenue expectations.
• Discount Rate has edged down marginally from 7.75% to 7.74%, suggesting a slightly lower risk premium assigned to the company.
• Revenue Growth projections are down modestly, with expectations decreasing from 5.67% to 5.59%.
• Net Profit Margin has improved slightly, rising to 23.19% from 23.14%. This indicates a small increase in projected profitability.
• Future P/E has decreased from 16.00x to 15.79x. This points to a modestly lower valuation multiple on forecasted earnings.